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ABSTRACT  6 
Introduction: Most of the current evidence regarding pneumococcal upper respiratory 7 
colonization in adults suggests that despite high disease burden, carriage prevalence is 8 
low. Contemporary studies on adult pneumococcal colonization have largely followed 9 
the pediatric approach by which samples are obtained mostly from the nasopharynx and 10 
bacterial detection is evaluated by routine culture alone. Recent evidence suggests that 11 
the “pediatric approach” may be insufficient in adults and pneumococcal detection in 12 
this population may be improved by longitudinal studies that include samples from 13 
additional respiratory sites combined with more extensive laboratory testing. 14 
Areas covered: In this article, relevant literature published in peer review journals on 15 
adult pneumococcal colonization, epidemiology, detection methods, and 16 
recommendations were reviewed.  17 
Expert opinion: Respiratory carriage of Streptococcus pneumoniae has been 18 
underestimated in adults. Contemporary pneumococcal carriage studies in adults that 19 
collect samples from alternative respiratory sites such as the oropharynx, saliva, or nasal 20 
wash; are culture-enriched for pneumococcus; and use molecular diagnostic methods 21 
designed to target two pneumococcal DNA sequences should enhance pneumococcal 22 
detection in the adult respiratory tract. This finding may have implications for the 23 
interpretation of dynamics of pneumococcal transmission and vaccination. 24 
 25 
Keywords: adults, carriage, colonization, pneumococcal, Streptococcus pneumoniae, 26 
upper respiratory tract 27 
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ARTICLE HIGHLIGHTS 28 
 Most of the evidence on pneumococcal upper respiratory tract carriage, associated 29 
implications, transmission, and dynamics following vaccination with pneumococcal 30 
vaccines have been obtained from studies performed in children. 31 
 32 
 In spite of the bimodal incidence of pneumococcal infections with peaks in children 33 
under 5 years and adults 65 years and older, conventional nasopharyngeal carriage 34 
studies in ≥65-year old adults have found low pneumococcal respiratory carriage 35 
(0%–6%). 36 
 37 
 Most carriage studies performed in adults have followed the pediatric approach in 38 
which a single swab from the nasopharynx, sometimes obtained together with an 39 
oropharyngeal sample, was collected and processed following standard culture 40 
recommendations. 41 
 42 
 Contemporary studies suggest that pneumococcal detection in the respiratory tract 43 
of adults has been underestimated and that pneumococcal detection in this age 44 
group is enhanced in longitudinal studies that obtain samples from various 45 
respiratory sites, such as nasal washes, oropharynx, and saliva and by the use of 46 





 Given the importance of understanding the dynamics of pneumococcal carriage in 50 
adults and the effect of pneumococcal conjugate vaccines on respiratory carriage, 51 
future studies in adults should implement additional molecular techniques to 52 
measure pneumococcal carriage in adults and the potential of adult-to-adult or adult-53 
to-children pneumococcal transmission. 54 
 55 
 56 
  57 
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1. INTRODUCTION  58 
A large proportion of pneumococcal disease burden is represented by non-bacteremic 59 
pneumonia in children and adults and otitis media in children, outcomes that are caused 60 
by extension of mucosal pneumococcal colonization [1-4]. Pneumonia is a major cause 61 
of mortality in children younger than 5 years, representing 16% of childhood deaths 62 
worldwide in 2016 [5,6]. The burden of community-acquired pneumonia (CAP) in adults is 63 
also substantial, especially in the elderly and those with comorbidities [7,8]. 64 
Many studies have attempted to estimate CAP etiology and burden in adults but have 65 
been limited by the sensitivity and specificity of currently available diagnostic tests [9]. 66 
Recently, however, the availability of pneumococcal serotype-specific urine antigen 67 
assays with high sensitivity and specificity has improved the detection of pneumococcal 68 
CAP in adults [10].  69 
Pneumococci commonly colonize the nasopharynx of young children, who are considered 70 
the major contributors to population transmission [1,11]. Colonization, also known as 71 
carriage, is considered a prerequisite for pneumococcal disease [1,12]. All people likely 72 
become colonized by pneumococci multiple times during their life, and colonization 73 
episodes typically resolve over days to months [11-13]. Pneumococcal disease peaks 74 
occur in children younger than 5 years and adults 65 years and older [14]; however, 75 
reported carriage prevalence has been higher among children than adults [15-29], 76 
which may partially explain why pneumococcal carriage studies have been most 77 
widely conducted in children [11,30-33]. 78 
Despite the wealth of information about pneumococcal carriage in children, information 79 
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regarding adult pneumococcal carriage and adult-to-adult and adult-to-children 80 
transmission is limited [34-36]. This review focuses on the available evidence regarding 81 
the epidemiology of pneumococcal colonization in adults, the discrepancies in 82 
colonization rates between children and adults, the differences in sample collection and 83 
laboratory processing, and current methodological recommendations. The goal is to 84 
identify best practices for evaluating adult pneumococcal carriage and to ascertain 85 
research gaps that may guide future studies on this topic.  86 
 87 
2. PNEUMOCOCCAL CARRIAGE IN THE PEDIATRIC RESPIRATORY 88 
TRACT: CURRENT UNDERSTANDING 89 
2.1 Epidemiology 90 
Most modern studies of pneumococcal respiratory tract carriage have been conducted in 91 
children [11-13,37-42]. Among unvaccinated children, the detected nasopharyngeal 92 
pneumococcal colonization prevalence varies but appears to be highest in infants and 93 
young children (depending on factors such as setting, geographic area, and 94 
colonization detection methods) and decreases with age [13,37,43,44]. In high-income 95 
countries, the mean age for pneumococcal acquisition is approximately 6 months, 96 
whereas in developing countries, it occurs as early as the first days of life to 3 months of 97 
age [11,25,45,46]. Differences in carriage burden and transmission, environmental 98 
conditions such as crowding, conditions that cause immune suppression such as 99 
measles, and pneumococcal immunization schedules and coverage [11,45,47-50] may 100 
contribute to this variability in the age of pneumococcal acquisition among young 101 
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children in developed versus developing economies. 102 
Pediatric carriage studies have provided useful information on the point prevalence of 103 
pneumococcal colonization among different populations [13,42,43,51,52]; 104 
characteristics of pneumococcal colonization, including carriage estimates by age and 105 
risk factors [13,53,54]; interactions between pneumococci and viruses or other 106 
bacterial pathogens [30]; disease-causing serotypes likely to emerge after vaccination 107 
with pneumococcal conjugate vaccines (PCVs) [42,55-59]; and invasive properties 108 
among diverse serotypes [32,60]. Pediatric carriage studies also provided early 109 
recognition of emerging antimicrobial resistance among pneumococcal strains 110 
[42,52,61,62], and of the relationship between antimicrobial use and resistance [33]. 111 
Additionally, carriage studies in children have contributed to our understanding of the 112 
direct and indirect effects of PCVs among vaccinated children and their contacts [63-66], 113 
and have been used to evaluate vaccine effectiveness [11]. Colonization data, when 114 
combined with information about the capacity of different strains to cause disease, are 115 
also used to understand and monitor the impact of vaccination on invasive disease 116 
prevalence [67]. Finally, pneumococcal carriage surveillance data have been considered 117 
by some groups as potential endpoints for pneumococcal vaccine licensure in children 118 
[68,69]. 119 
2.2 Assessment Methodology  120 
The World Health Organization (WHO) recommendations for detecting pneumococcal 121 
carriage in children call for the collection of a single nasopharyngeal swab (Fig. 1A) [70]. 122 
This recommendation is based on minimal improvements in sensitivity achieved with 123 
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additional sampling, coupled by potential discomfort for the child [70]. Oropharynx 124 
sampling in children is not advocated because the added yield is small, and sampling 125 
sensitivity of the nasopharynx alone may be >90% [70,71]. Given that new molecular 126 
technologies are increasingly being used [15,35,36], controlled studies comparing 127 
sampling sensitivity between the nasopharynx and alternative sites associated with less 128 
discomfort would be valuable. 129 
Nasopharyngeal swabs are placed in a transport medium upon collection [70]. Skim milk-130 
tryptone-glucose-glycerin (STGG) medium is most commonly used, allowing recovery of 131 
live pneumococci after long-term storage at ultra-low temperatures (ie, –70°C or lower). 132 
Commercial media are also used, of which Amies transport medium is an example. To 133 
be stored frozen in Amies, glycerol needs to be added to the sample [35]. For samples to 134 
be tested with molecular tests (ie, real-time PCR), universal transport 135 
mediumcontaining vials can be used. 136 
Further considerations must be observed regarding methodologies for colony 137 
identification and pneumococcal serotyping. For pneumococcal detection, 138 
nasopharyngeal samples are cultured on blood agar supplemented with 5 µg/mL 139 
gentamicin, which suppresses non-streptococcal species growth [70]. Pneumococcal 140 
identification has typically used isolates displaying a classic phenotype (alpha-hemolytic 141 
colonies) that are optochin susceptible and bile soluble [70]. In most pediatric carriage 142 
studies [32,41,43,70], pneumococci are serotyped by the capsular reaction/swelling test 143 
(Quellung reaction or Neufeld test [Statens Serum Institut, Copenhagen, Denmark]), 144 
which is the current “gold standard” method recommended by the WHO [70]. This is in 145 
part because of the experience using this methodology as part of the PCV clinical 146 
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development program including carriage studies (Dr. Katherine O’Brien, unpublished 147 
data). However, this method is labor-intensive, expensive, and requires the selection of a 148 
single colony for characterization; therefore, it is poorly suited to detecting carriage of 149 
multiple serotypes unless they are phenotypically distinct on the culture plate [36,70,72]. 150 
DNA-based approaches have also been developed for detection and serotyping, 151 
including microarray, sequencing, and traditional or quantitative PCR (qPCR) [73-75]. 152 
These approaches have been demonstrated to be highly sensitive in previous studies 153 
[15,36,76], and potentially represent a viable method for sample detection in children. 154 
However, caution is needed in interpreting PCR-serotyping assays performed directly on 155 
clinical samples because of suspected non-pneumococcal homologs of genes previously 156 
thought to be serotype-specific pneumococcal genes [77,78]. 157 
In some protocols, samples are passed through an initial broth culture step for further 158 
enrichment, such as the enrichment broth developed at the US Centers for Disease 159 
Control and Prevention that increases sensitivity of pneumococci detection by either 160 
conventional culture on agar medium or by molecular methods (Figure 1B) [79]. 161 
Alternatively, swabs can be tested with real-time PCR [80-84], which is suitable for 162 
diagnosis and serotyping and can detect co-carriage of multiple serotypes when present 163 
[85]. However, result interpretation requires caution because of potential false-positive 164 
findings [86,87]. 165 
In summary, most contemporary investigations of pneumococcal respiratory tract 166 
carriage have been conducted in children [11-13,37-42]. In children, it is recommended 167 
that a single nasopharyngeal swab be collected for culture-based pneumococcal 168 
carriage detection and serotyping using the capsular reaction/swelling test [70]; DNA-169 
12 
 
based approaches with high sensitivity are also available for detection and serotyping 170 
[15,36,73-76] but limitations exist [77,78,86,87]. 171 
 172 
3. PNEUMOCOCCAL COLONIZATION IN THE ADULT RESPIRATORY 173 
TRACT: CURRENT UNDERSTANDING 174 
3.1 Divergent Epidemiology in Children and Adults 175 
Although older adults, particularly those aged ≥65 years, are at high risk of 176 
pneumococcal disease [16,88,89], pneumococcal respiratory carriage in adults has not 177 
been well characterized [24,81]. Moreover, despite disease peaks in young children and 178 
older adults, substantial differences in pneumococcal colonization prevalence between 179 
these populations are reported when comparable detection methods are used [36]. 180 
Detection of pneumococcal colonization with nasopharyngeal cultures is high among 181 
pediatric populations [11,53], but infrequent among ≥65-year old adults (0%–6%) [18-182 
20,22,26,29,90-95] (Table 1). A number of potential explanations for the discrepancies 183 
in pneumococcal carriage prevalence between children and adults have been 184 
suggested. One relates to the maturation of the innate immune system with age and the 185 
development of serotype-specific immunity from multiple exposures during the first 186 
years of life resulting in short duration colonization episodes [16,19,96,97]. Additionally, 187 
studies have shown that adults have reduced pneumococcal receptors in the 188 
nasopharynx [16,19]. The combination of these characteristics may lower the 189 
pneumococcal density in the respiratory tract of adults compared with that of children or 190 
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may change the preferred ecological niche from the nasopharynx in children to the oral 191 
cavity in adults (Figure 2).  192 
3.2 Assessment Methodology 193 
The conundrum of differing carriage prevalence between children and older adults is 194 
compounded by a relative paucity of contemporary data evaluating best methods and 195 
outcomes to evaluate pneumococcal carriage in adults. Determining the most accurate 196 
and biologically relevant means of measuring pneumococcal colonization in the adult 197 
respiratory tract is essential. For example, if colonization prevalence is incorrectly 198 
characterized as low in a population with high disease incidence because of insensitive 199 
methods, it may be erroneously concluded that enhanced invasiveness of certain 200 
serotypes exists in this population [98]. Alternatively, if low density colonization with 201 
subdominant strains is not biologically relevant for disease epidemiology, detecting 202 
these strains with highly sensitive assays may lead to incorrect conclusions about 203 
inherent strain characteristics. 204 
Early studies measuring pneumococcal carriage in healthy adults collected only oral 205 
samples (saliva, throat swabs, or washes) and used mouse inoculation animal models 206 
[99-104]. These studies reported pneumococcal carriage prevalence values of 21% to 207 
94% across all ages (Figure 3) [16,99-104], suggesting that current adult pneumococcal 208 
carriage prevalence may be underestimated if only nasopharyngeal cultures are 209 
analyzed.  210 
Furthermore, recent studies suggest that adult pneumococcal carriage is more common 211 
than estimated previously and that the underestimation results from the use of 212 
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insensitive diagnostic tools (eg, limiting sampling to the nasopharynx, testing only by 213 
culture) [15,35,36,97]. These contemporary studies, described in detail below, used 214 
samples obtained from various sites, such as the nasopharynx, oropharynx, and saliva, 215 
and used molecular-based methods targeting specific conserved sequences of 216 
pneumococcal DNA [35,97]. 217 
3.3 Sampling Location for Adult Pneumococcal Carriage: Nasopharynx, 218 
Oropharynx, or Saliva  219 
The optimal respiratory site for collection and identification of adult pneumococcal 220 
carriage is less clear than in children. The WHO updated their recommendations in 221 
2013 accordingly, advising to include collection of both nasopharyngeal and 222 
oropharyngeal samples from adults, with prioritization of nasopharyngeal samples if 223 
sampling from only a single site is possible [70]. Nasal wash and oral cavity sample 224 
collection are better tolerated by participants, and some studies report oropharyngeal 225 
and saliva samples to be more informative for pneumococcal detection than 226 
nasopharyngeal samples in adults [15,16,35,36,70,105,106]. 227 
The WHO recommendation does not include collection of saliva samples or use of 228 
molecular-based diagnostic methods for adult samples, and the addition of 229 
oropharyngeal samples for culture only have not improved the detection of pneumococci 230 
in samples from adults [27,28,34-36]. 231 
Although saliva samples obtained from healthy adults and inoculated in the animal 232 
model were successfully used in early pneumococcal surveillance studies [99-104], 233 
ethical limitations exist with this approach. Currently, the main difficulty with the use of 234 
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oral samples for pneumococcal detection is their polymicrobial nature, being rich in 235 
respiratory aerobic and anaerobic bacteria, including pathogenic and nonpathogenic 236 
species of Haemophilus sp, Neisseria sp, and Staphylococcus sp, and various alpha 237 
hemolytic non-pneumococcal streptococci [16,107,108]. This complicates identification 238 
and isolation of pneumococci, with some streptococcal species producing atypical 239 
results in classical diagnostic assays; therefore, the use of multiple subcultures on 240 
selective medium or molecular diagnostic methods are required [16,76,78,87,107-110]. 241 
3.4 Molecular Techniques for Pneumococcal Identification in the Respiratory 242 
Tract of Adults  243 
Because of the suspicion that culture-based pneumococcal detection methods are 244 
insensitive in adults, recent surveillance studies have evaluated the use of molecular-245 
based detection technologies that target specific bacterial DNA sequences  246 
[15,29,35,36,71,85,111]. Several PCR-based diagnostic tests for pneumococcal 247 
identification have been proposed [15,78,108,112-115], but their usefulness has been 248 
hampered by a lack of specificity and sensitivity. Currently, the most promising 249 
approaches are real-time PCR–based assays targeting specific sequences of lytA (the 250 
major autolysin) in combination with the detection of SP2020 (a putative transcriptional 251 
regulator) or piaB (a permease gene of the pia ABC transporter) [15,76,78,116]. 252 
One of the benefits of molecular-based methods is that, unlike the Quellung test, they 253 
do not require a pure isolate and can be performed directly on human fluid such as 254 
respiratory samples and can detect the presence of multiple serotypes. They also may 255 
be useful in cases in which antimicrobial treatment has started [116-118]. Real-time 256 
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PCR (or qPCR) has greater sensitivity than multiplex sequential PCR in serotyping 257 
pneumococci [85,87,116]. 258 
A major concern with molecular diagnostic tests for identifying pneumococci among 259 
respiratory samples is the possibility of nonspecific or misleading results. False positive 260 
signals may occur because of the presence of non-pneumococcal streptococci carrying 261 
homologous pneumococcal genes, particularly in oral samples, which may produce 262 
misleading signals [78,86,87,119]. Additionally, the detection of pneumococcal DNA in 263 
saliva does not necessarily indicate that bacteria are viable or important contributors to 264 
disease risk [36,87]. Additional studies are necessary to further support the specificity of 265 
molecular diagnosis for the detection of adult pneumococcal carriage and to show the 266 
potential for positive saliva samples to contribute to transmission [120]. Molecular 267 
methods currently used for pneumococcal detection in the respiratory tract are more 268 
sensitive and specific than those previously used and involve qPCR testing for specific 269 
genes within culture-enriched samples and use of stringent definitions [15,35,36,76]. 270 
PCR testing has the disadvantage of potential non-specificity [121], with detection of 271 
pneumococcal DNA even if this reflects a situation with little clinical or biological 272 
consequences (eg, density so low that transmission does not occur or having genetic 273 
material carried by non-pneumococcal Streptococci). As assay sensitivity may be 274 
pushing the limits of our interpretive understanding, it is critical that studies address this 275 
issue. 276 
In summary, the optimal respiratory site for detection of pneumococcal carriage in adults 277 
is not well elucidated and molecular-based detection methods are being developed to 278 
improve sensitivity and to define additional outcomes such as density; these approaches 279 
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have both benefits and limitations [15,16,35,36,70,78,105,106,108,112-115]. Described 280 
below and summarized in Table 2 are studies in adults comparing different sampling 281 
sites and detection assays and assay refinement methods for assessing pneumococcal 282 
colonization.  283 
 284 
4. STUDIES ASSESSING METHODOLOGIES USED IN CARRIAGE 285 
STUDIES IN ADULTS 286 
4.1 Assessment of Sampling Sites and Detection Methods 287 
To evaluate various respiratory niches, a cross-sectional study conducted in Israel 288 
examined the importance of nasopharyngeal and oropharyngeal samples for the 289 
detection of pneumococci in 216 children 5 years and younger and their mothers [71]. A 290 
single sample of each type was obtained from each participant. Respiratory samples 291 
were inoculated onto Columbia agar plates with 5% sheep blood and 5 µg/mL 292 
gentamicin; bacterial identification followed standard recommendations. 293 
Nasopharyngeal samples alone would have missed only 2% of overall pneumococcal 294 
isolates cultured in children but 42% of overall pneumococcal isolates cultured in 295 
mothers, while oropharyngeal cultures alone would have missed 73% of pneumococcal 296 
isolates in children and 45% of maternal isolates. These findings suggest that 297 
nasopharyngeal cultures alone are sufficient in children, whereas both nasopharyngeal 298 
and oropharyngeal cultures are needed in parent-aged adults to optimize pneumococcal 299 
colonization detection. 300 
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Two recent studies found a low pneumococcal colonization prevalence among adults 301 
65 years and older, highlighting the complexity of pneumococcal colonization studies in 302 
adults (Table 1) [28,29,81,122]. The first was a multicenter surveillance assessment of 303 
prevalence and serotype distribution of pneumococcal carriage in individuals 65 years 304 
and older at centers in four US states [28,81]. Samples (1 each) from the nasopharynx 305 
and oropharynx were collected for routine culture. Along with conventional culture-306 
based diagnostic screening, all samples underwent molecular testing using qPCR 307 
targeting lytA, as described previously [113]. Among 2989 samples, pneumococcal 308 
carriage prevalence was 1.8%, with 1.5% prevalence based on culture-positive samples 309 
from the nasopharynx or oropharynx and 0.3% lytA-positive samples from 310 
nasopharyngeal samples [81]. These findings are similar to the prevalence of adult 311 
pneumococcal colonization reported from other studies using nasopharyngeal samples 312 
[16,19,22,35]. However, important limitations of this study were that qPCR testing was 313 
only performed among nasopharyngeal samples, and saliva samples were not obtained 314 
thereby precluding definitive characterization of the pneumococcal colonization 315 
prevalence in this population. 316 
The second study was a cross-sectional, prospective assessment that enrolled 317 
participants of all ages from the Navajo Nation and White Mountain Apache Tribal lands 318 
in the southwest United States between October 2015 and November 2017 [29,122]. 319 
These communities have historically high prevalence of pneumococcal colonization in 320 
children and pneumococcal infections in children and adults [29,123,124]. 321 
Nasopharyngeal swabs for culture were collected at all ages, and a sample from the 322 
oropharynx was additionally collected from adults [29,122]. Both samples were collected 323 
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using flocked swabs, inoculated into STGG, and cultured initially in broth enrichment 324 
media [29]. Nasopharyngeal carriage prevalence by culture was 49.5% (297/600) in 325 
children younger than 5 years, 8.9% (53/597) in adults 18 to 64 years of age, and 6.0% 326 
(18/299) in adults 65 years and older. Similar to the previous study, limitations of this 327 
study are that saliva samples were not collected from adults, and qPCR results were 328 
absent. However, the authors of this study suggested the need for supplementary 329 
studies to determine the optimal sampling site and diagnostic assay [29]. 330 
Additionally, a recently published cross-sectional study evaluated the differences 331 
between culture-based and molecular methods in detecting pneumococcal 332 
nasopharyngeal colonization and the effects of age and colonization density on 333 
detection in healthy individuals [125]. Nasopharyngeal specimens were assessed from 334 
982 healthy individuals (median age: 18.7 years) from 2010 to 2012 on the Navajo 335 
Nation and White Mountain Apache Tribal lands in the United States. Overall, samples 336 
from 35% of participants underwent broth-enrichment culture and 60% of samples were 337 
qPCR positive for lytA, with a 71% agreement between the two diagnostic tests. 338 
Interestingly, S pneumoniae was detected more frequently among samples with higher 339 
bacterial density while qPCR improved pneumococcal detection among adults 18 years 340 
and older with lower pneumococcal density [125].  341 
Results from a longitudinal surveillance study designed to document cumulative 342 
incidence of pneumococcal colonization in adults 65 years and older were recently 343 
published [97]. One hundred community-dwelling adults from Rochester, New York, 344 
were recruited in 2015 and followed up for 12 months. Nasopharyngeal and 345 
oropharyngeal samples were obtained bimonthly. DNA was extracted from broth-346 
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enhanced medium and tested in real-time PCR amplifying lytA. Colonization was 347 
defined as at least one oropharyngeal or nasopharyngeal sample positive for lytA via 348 
PCR as described previously [113]. PCR-positive samples were subcultured on 349 
gentamicin blood agar plates to identify and serotype pneumococci [97]. During the 12-350 
month surveillance period, 57 colonization events among 41 participants were 351 
observed, resulting in a 12-month cumulative colonization prevalence of 41% by PCR 352 
and 14% by culture. Among 149 lytA-positive samples, viable pneumococci were 353 
isolated in 11% of samples, with pneumococcal-like isolates grown from oropharyngeal 354 
(56.4%), nasopharyngeal (25%), or from combined broth-enhanced samples (18.6%) 355 
[97]. The possibility of detecting false signals from the respiratory tract has been 356 
reported previously [107]. Nevertheless, use of qPCR methods targeting at least two 357 
pneumococcus-unique sequences (eg, lytA, piaB) should diminish the possibility of 358 
false-positive results [15,35,36].  359 
In consideration of the limitations observed in pneumococcal sampling and detection in 360 
adults described above, studies conducted in the Netherlands provide insights 361 
regarding methodologic considerations for assay refinement (Figure 1C). The first, 362 
which was performed during the fall/winter seasons of 2010 and 2011, used paired 363 
nasopharyngeal and oropharyngeal samples from 268 parents of 24-month-old children 364 
[15]. Nasopharyngeal samples were obtained using standard flexible swabs, and 365 
oropharyngeal samples were collected using rigid swabs under direct observation of the 366 
pharynx. Samples were cultured on agar selective for streptococci and harvests of all 367 
colony growth from these plates were considered to represent samples culture-368 
enricheded for pneumococci. Extracted DNA were tested with qPCR for sequences 369 
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unique for lytA and piaB and considered positive for pneumococci when both targets 370 
were detected. While routine culture was as sensitive as molecular methods in detecting 371 
pneumococci in adult nasopharyngeal samples, routine culture sensitivity was low when 372 
oropharyngeal samples were tested. The number of oropharyngeal samples identified 373 
as positive for pneumococci dramatically increased when culture-enriched samples 374 
were analyzed with molecular methods or revisited with a second culture stage after 375 
positivity had been determined by qPCR. Additionally, oropharyngeal samples were 376 
superior to nasopharyngeal samples in pneumococcal carriage detection whether tested 377 
with culture or molecular methods. Findings for this age group were supported in a 378 
second study, which applied similar methods as well as saliva sampling, the latter of 379 
which resulted in superior molecular surveillance compared with nasopharyngeal 380 
sampling [126].  381 
The authors reached several conclusions [15]. Underreporting of pneumococcal 382 
respiratory tract colonization in adults can occur if only routine nasopharyngeal or 383 
oropharyngeal cultures are obtained. Oropharyngeal was superior to nasopharyngeal 384 
sampling for detecting pneumococcal colonization when tested by qPCR. The use of 385 
qPCR testing can identify samples that produce viable pneumococcal isolates through 386 
further laboratory processing and with strict controls in place. Thus, this method may 387 
achieve higher sensitivity and specificity for the detection of pneumococci in the 388 
respiratory tract of adults and children. 389 
Another study from the same group compared pneumococcal colonization prevalence 390 
among respiratory sites using different detection methods in older adults [35]. Samples 391 
from the nasopharynx, oropharynx, and saliva (270 per sample type) were collected 392 
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during the autumn/winter of 2011/2012 from 135 persons 60 to 89 years of age at the 393 
onset of influenza-like illness and 7 to 9 weeks later, after recovery from influenza-like 394 
illness. Nasopharyngeal samples were collected and processed as noted for the 395 
previous studies [15,36], and saliva samples were collected using a saliva collection 396 
system. qPCR was used to detect the lytA and piaB pneumococcal genes. Samples 397 
were considered positive for pneumococci when both genes were detected. Overall 398 
detection of pneumococcal carriage was higher via the molecular method (34%) versus 399 
culture (6%). Of note and as described above, by revisiting samples testing positive for 400 
pneumococci by the molecular method with additional culture steps, the number of 401 
culture-positive samples increased. Additionally, the number of saliva samples classified 402 
as pneumococcal-positive by the molecular method increased significantly by testing 403 
culture-enriched samples compared with uncultured saliva samples (ie, raw, direct 404 
testing). As in other studies [15,107], these data support the use of an enrichment step 405 
and suggest that viable pneumococci, rather than solely pneumococcal DNA, are the 406 
source of the signal. When considered together, these two studies highlight the 407 
importance of vigilance and using proper methods for detecting pneumococci in adults 408 
[15,35,126]. 409 
4.2 Experimental Human Pneumococcal Carriage Model 410 
The experimental human pneumococcal carriage (EHPC) model was recently 411 
developed, allowing for fast, safe, and accurate analysis of the interaction between 412 
pneumococcal serotypes 6B, 15B and 23F in the upper respiratory tract and host [127] 413 
(and Dr. Daniela Ferreira, unpublished data from 14th European Meeting on the 414 
Molecular Biology of the Pneumococcus). This model has been tested in at least 1000 415 
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healthy adult volunteers (Dr. Daniela Ferreira, unpublished data), including vaccine 416 
efficacy studies, and is being studied in patients with mild, well-controlled asthma [127-417 
129].  418 
The EHPC is an important platform to understand microbiologic and mucosal properties 419 
associated with pneumococcal colonization in the respiratory tract. Volunteers are nasal 420 
inoculated with a pneumococcal strain diluted in saline at a determinate bacterial 421 
concentration [127]. Samples of various respiratory tract sites are then obtained, 422 
allowing analysis of host and bacterial properties associated with pneumococcal 423 
colonization, longitudinal follow-up of participants, and assessment of pneumococcal 424 
vaccine effects in preventing colonization.  425 
Approximately 10% to 60% of volunteers become colonized following nasal inoculation 426 
within the EHPC protocol; this percentage varies depending on the serotype used (Dr. 427 
Daniela Ferreira, unpublished data from 14th European Meeting on the Molecular 428 
Biology of the Pneumococcus). The carriage prevalence is approximately 60% for the 429 
serotype 6B model, approximately 31% for serotype 15B, and approximately 10% to 430 
16% for serotype 23F. The model has also estimated that after serotype 6B colonization 431 
is achieved, it remains detectable for approximately 22 days (Dr. Daniela Ferreira, 432 
unpublished data). 433 
Data from the EHPC studies indicate that after nasal inoculation, respiratory 434 
colonization can take up to 24 hours to become established [130]. Individuals 435 
successfully colonized after nasal inoculation with serotype 6B lacked cytokine and 436 
neutrophil responses during the first hours and days following exposure, and bacterial 437 
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DNA was not found during the initial hours in saliva. Eight hours after nasal inoculation, 438 
pneumococcal density starts to decline in the anterior nares, suggesting the occurrence 439 
of pneumococcal migration toward the nasopharyngeal site, strong epithelial binding, or 440 
internalization of the pneumococci.  441 
Among volunteers in whom nasal inoculation failed to establish respiratory colonization, 442 
the EHPC model identified two distinct pneumococcal clearance profiles [130]. The first 443 
group consisted of nasal clearers, among whom an immediate local bacterial clearance 444 
occurred and was associated with a strong baseline neutrophil activation and lack of 445 
proinflammatory response or bacterial clearance to the saliva. For these individuals, the 446 
model suggested that neutrophils play an important role in the prevention of 447 
pneumococcal colonization. A second path for pneumococcal clearance was observed 448 
in a group of individuals for whom pneumococci quickly reached the saliva, most likely 449 
because of effective nasal mucociliary activity (saliva clearance). Saliva clearers 450 
induced a strong proinflammatory response in the first day after exposure associated 451 
with concurrent induction of neutrophil responses.  452 
The EHPC model was used to analyze the impact of 13-valent PCV (PCV13) on 453 
pneumococcal colonization in the respiratory tract of 100 healthy participants 18 to 50 454 
years of age [128]. Participants in this double-blind placebo-controlled trial were 455 
randomly assigned to receive PCV13 (n=49) or hepatitis A vaccine (HAV; n=50) 456 
followed by inoculation with 80,000 CFU/100 mL of pneumococcal serotype 6B. 457 
Participants were followed for 21 days to determine pneumococcal colonization by 458 
routine culture of nasal wash. The PCV13 group had an overall significantly reduced 6B 459 
colonization prevalence (10%) compared with the HAV group (48%; P<0.001). At 3 460 
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weeks postvaccination, the serotype 6B colonization prevalence was 4.3% in the 461 
PCV13 group and 33.3% in the HAV group. Density of colonization and the area under 462 
the curve (density vs day) were reduced in the PCV13 compared with the HAV group 463 
following inoculation.  464 
 465 
5. CONCLUSION 466 
Adults 50 years and older, especially the elderly (ie, 65 years and older), represent a 467 
particularly vulnerable population for pneumococcal disease. Despite this, there is a 468 
relative dearth of information regarding pneumococcal respiratory colonization and 469 
transmission in adults. Here, we reviewed the available evidence and highlighted the 470 
overall low detection rates of adult pneumococcal colonization using nasopharyngeal 471 
cultures, a striking contrast to pediatric populations where both disease incidence and 472 
colonization rates are high. However, contemporary studies suggest that detection of 473 
pneumococcal colonization in adults can be improved by incorporating additional 474 
respiratory sampling sites and sensitive culture- and molecular-based techniques. Future 475 
studies should consider implementing these methodologies to further elucidate adult 476 
pneumococcal colonization and transmission dynamics to better guide preventative and 477 
therapeutic interventions.    478 
In conclusion, based on the evidence reviewed herein, samples from the nasopharynx, 479 
oropharynx, and saliva should be obtained from adults 65 years and older for detection 480 
of pneumococci by culture and qPCR; the use of qPCR should be implemented with 481 
caution and ideally should target at least two pneumococcal genes. Depending on the 482 
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study objectives, samples may need to be collected longitudinally at prespecified time 483 
points.  484 
 485 
6. EXPERT OPINION  486 
Pneumococcal infection can progress to serious and sometimes fatal illness, with 487 
children and older adults at greatest risk [37]. While most children are transiently 488 
colonized at a young age [1], the prevalence of carriage reported in adults has 489 
generally been substantially lower than in children [16]. The current paradigm for the 490 
transmission of pneumococci argues that transmission occurs from toddlers and young 491 
children to all age groups [1,11].  492 
PCV immunization programs for pediatrics have been very effective in decreasing 493 
acquisition and carriage of most vaccine-type pneumococci among children and 494 
interrupting transmission to unvaccinated populations including adults [131]. Importantly, 495 
reduction in the transmission of pneumococci has led to large indirect declines of 496 
vaccine-serotype pneumococcal disease in both pediatric and adult populations [63-66]. 497 
Recent surveillance data have, however, shown region-specific trends toward increased 498 
prevalence of certain pneumococcal serotypes in adults, despite highly effective pediatric 499 
immunization programs [1,132]. For these reasons, the accurate assessment of 500 
pneumococcal colonization in adults, particularly in those older than 65 years, is 501 
essential for a clear understanding of the biological link and risk of colonization events 502 
for pneumococcal disease. In addition, data on carriage from adults may provide 503 
valuable information that can help guide preventative and therapeutic interventions.  504 
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Previous studies on pneumococcal colonization in adults have followed the pediatric 505 
approach, with sampling of the nasopharynx for routine cultures [18-20,26,133]. 506 
However, data suggest that methods to assess pneumococcal colonization in adults 507 
should differ from those used in children [15,35,36,97]. Establishing robust practices for 508 
sampling to investigate pneumococcal colonization in adults is more complex than in 509 
children [70].  510 
Further studies assessing the sensitivity and specificity of testing various respiratory 511 
niches, and that evaluate different diagnostic modalities, are needed to establish 512 
recommendations that are evidence based, including systematic evaluation of emerging 513 
data and the development of standards for colonization studies in adults. Initial studies 514 
should include sampling of all respiratory sites—such as the nasopharynx, oropharynx, 515 
saliva, and nasal washes—for S pneumoniae detection with standard cultures and using 516 
molecular diagnostic methods.  517 
Overall, we think that pneumococcal carriage in adults has largely been underestimated 518 
to date. However, we speculate that the findings discussed here highlight key limitations 519 
and approaches to pneumococcal carriage studies in adults and will thereby steer future 520 
studies towards best practices in understanding pneumococcal transmission and 521 
vaccination dynamics.  522 
During the next 5 years, we expect that implementing the collection and laboratory 523 
assessments discussed in this review will demonstrate higher colonization rates in 524 
adults, with some degree of adult-to-adult and adult-to-childhood pneumococcal 525 
transmission that might be prevented with the use of conjugated pneumococcal 526 
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vaccines in the population of older adults. This better understanding of adult 527 
pneumococcal colonization and transmission is key for guiding preventative and 528 
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One. 2013;8(3):e60520.  1011 
 Using paired nasopharyngeal and oropharyngeal samples from 268 parents of 1012 
children younger than 24 months in the Netherlands, detection of pneumococcal-1013 
positive oropharyngeal samples was substantially increased when culture-1014 
enriched samples were analyzed with molecular methods (qPCR for lytA or piaB) 1015 
or revisited with a second culture stage; overall, pneumococcal carriage 1016 
detection rates were significantly higher in oropharyngeal compared with 1017 
nasopharyngeal samples. 1018 
** 16. Krone CL, van de Groep K, Trzcinski K, et al. Immunosenescence and 1019 
pneumococcal disease: an imbalance in host-pathogen interactions. Lancet 1020 
Respir Med. 2014;2:141-153. 1021 
 This is a valuable review of the immunological factors involved in adult 1022 
pneumococcal colonization and disease (eg, age-associated differences in the 1023 
mucosa and immunosenescence of the innate immune system), highlighting 1) 1024 
how reliance on certain diagnostic methods (eg, nasopharyngeal sampling) may 1025 
potentially underestimate pneumococcal respiratory carriage in adults and 2) how 1026 
earlier pre-antibiotic studies using saliva and animal inoculation methods 1027 
reported higher adult pneumococcal colonization rates. 1028 
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* 92. Branche AR, Yang H, Java J, et al. Effect of prior vaccination on carriage rates of 1045 
Streptococcus pneumoniae in older adults: A longitudinal surveillance study. 1046 
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 This study showed the importance of longitudinal pneumococcal carriage 1048 
surveillance in adults and the potential value of molecular diagnostic methods 1049 
versus standard cultures alone.  1050 
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* 122. Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a 1051 
pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir 1052 
Crit Care Med. 2015;192:853-858. 1053 
 This study demonstrated the beneficial effect of PCV13 in the human 1054 
experimental challenge model inoculated with S pneumoniae serotype 6B; 1055 
compared with a control group vaccinated against hepatitis A, PCV13 recipients 1056 
showed greater protection against pneumococcal colonization and a significantly 1057 
lower bacterial density in those participants who were colonized.  1058 
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Table 1. Pneumococcal Colonization of the Upper Respiratory Tract of Healthy Adults Identified by Cultures Only 1060 







Adler et al [90] Community (2010–
2017) 
≥18 y 795 NP 6.5 
Hammitt et al [91] Community (2009–
2017) 
≥18 y 1978 NP 21.7 




≥65 y 210 NP 1.9 
Grant et al [92] Community (2010–
2012) 
≥18 y 6628 NP 13 
Sutcliffe et al [93] Community (2010–
2012) 
≥18 y 513 NP 8–12 
Roca et al [94] Community (2010) ≥15 y 398 NP 17.6 
Regev-Yochay et al 
[20] 
Parents of 
children aged ≤5.5 y 




Palmu et al [22] Community (2003–
2004) 
≥65 y 590 NP 0.0‒5.9 
Abdullahi et al [95] Community (2004) ≥50 y 107 NP 4.7 
Regev-Yochay et al 
[19] 
Community (2001) Adults 1300 NP 3.7 
Saravolatz et al [18] Military (NR) Adults 200 NP 1.5 














Putnam et al [21] Military (1994–1995) Adults 915 OP 1.2 
Milucky et al [81] Community (2015–
2016) 
≥65 y 2989 NP, OP 1.8 
Almeida et al [34] Community (2010–
2012) 
>60 y 3361 NP, OP 2.3 
Van Gils et al [133] Parents of Adults 953 NP, OP 24.4 
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children aged 12 mo  
Parents of children 
aged 24 mo (2005–
2008) 
Adults 926 NP, OP 19.9 
Levine et al [24] Military (2007) Adults 742 NP, OP 10.8 
Ridda et al [17] Hospitalized elderly 
(2005–2006) 
≥60 y 315 NP, OP 0 
Millar et al [23] Adults (1997–2000) ≥65 y 70 NP, OP 9 
NP=nasopharyngeal; NR=not reported; OP=oropharyngeal. 1061 
  1062 
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Table 2. Pneumococcal Colonization of the Upper Respiratory Tract of Healthy Adults Identified by Cultures 1063 
and/or qPCR  1064 
Study Year Country 
Number of 




Krone et al [35] 2011–2012 Netherlands 135 ≥60 y NP Culture 6/270 (2) 
qPCR 13/270 (5) 
OP Culture 10/270 (4) 
qPCR 31/270 (11) 
Saliva Culture 6/270 (2) 




Culture 0/270 (0) 
qPCR 6/270 (2) 
NP, OP, 
or saliva 
Culture 15/270 (6) 
qPCR 91/270 (34) 
Martinelli et al 
2016 [132] 
2013–2015 Italy 195 ≥65 y NP qPCR 76/195 (39) 
Ansaldi et al 2013 
[135] 
2012 Italy 283 ≥60 y NP qPCR 53/283 (19) 
Suzuki et al 2006 
[115] 
NA Japan 30 ≥60 y Saliva qPCR 11/30 (37) 
Trzciński et al 
2013 [15] 
2010–2011 Netherlands 268 Parents NP Culture 49/268 (18) 
qPCR 50/268 (19) 
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OP Culture 10/268 (4) 
qPCR 94/268 (35) 
NP and 
OP 
Culture 7/268 (3) 
qPCR 39/268 (15) 
OP or 
NP 
Culture 52/268 (19) 
qPCR 105/268 (39) 




100 Parents NP qPCR 9/100 (9.0) 
606 ≥65 y NP qPCR 13/599 (2.2) 
Becker-Dreps et al 
[26] 
2010 United States 210 ≥65 y NP qPCR 4/210 (1.9) 
Almeida et al [134] 2015–2016 Portugal 87 25–50 y NP, OP, 
and 
saliva 
qPCR 25/87 (28.7) 
Flamaing et al 
[136] 
NA Belgium 503 80 y 
(mean) 
NP qPCR 21/503 (4.2) 
Esposito et al 
[137] 
2015 Italy 417 All ages OP qPCR 41/417 (9.8) 
246 <75 y 28/246 (11.4 
171 ≥75 y 13/171 (7.6) 
van Duersen et al 
[138] 
 
2007–2008 Netherlands 330 ≥65 y NP Culture 16/330 (5) 
qPCR 32/330 (10) 
OP Culture 16/330 (5) 
qPCR 58/330 (18) 
NP and 
OP 
Culture 7/330 (2) 





Culture 25/330 (8) 
qPCR 71/330 (22) 
Sutcliffe et al [125]    2010–2012 United States 63 >50 NP Culture 18/63 (29) 
      qPCR 24/63 (38) 
NA=not available; NP=nasopharyngeal; OP=oropharyngeal; qPCR=quantitative PCR. 1065 
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FIGURE LEGENDS 1066 
Figure 1. Standard diagnostic methods for the detection of pneumococci from the 1067 
respiratory tract of children and adults. A. Pediatric method [70], B. Adult method 1068 
without enrichment medium for pneumococcal growth and enhancement of DNA 1069 
extraction used in the study by the CDC [81], and C. Adult method with samples culture-1070 
enriched for pneumococcal growth used in the Netherlands [15,35,87,126]. CDC=US 1071 
Centers for Disease Control and Prevention; NP=nasopharyngeal; OP=oropharyngeal; 1072 
qPCR=quantitative polymerase chain reaction; smPCR=single molecule polymerase 1073 
chain reaction; STGG=skim milk-tryptone-glucose-glycerin. *Before placing on dry ice, 1074 
saliva is supplemented with 10% (final concentration) glycerol; †all samples tested 1075 
independent of lytA and piaB qPCR results; §samples positive for pneumococci when 1076 
tested with molecular method. 1077 
Figure 2. Dynamics of pneumococcal colonization in the upper respiratory tract of 1078 
children and adults [12,16,19,139,140]. qPCR=quantitative polymerase chain reaction. 1079 
Figure 3. Pneumococcal prevalence from the oral cavity of adults in early studies 1080 
[16,99-104]. *Data are reported in Krone et al [16]. 1081 
  1082 
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